Aleph Therapeutics, Inc

Eiger Biopharmaceuticals is a research-driven biopharmaceutical company based in Palo Alto, CA. The company focuses on developing innovative therapies for serious diseases with unmet medical needs. Utilizing cutting-edge technology and scientific expertise, Eiger Biopharmaceuticals is dedicated to advancing novel treatments to improve patient outcomes and quality of life. Generated from their business information

NeuCyte, Inc. is an innovative biotechnology company based in Mountain View, CA, specializing in CNS drug discovery. With their proprietary SynFire technology, they have developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling, focusing on genetically defined neurological diseases such as Alzheimer's disease, ALS, Epilepsy, and Fragile X Syndrome. NeuCyte's mission is to accelerate and optimize CNS drug discovery by developing more predictive assays and platforms for phenotypic screening, addressing the high attrition rate of novel CNS drugs during clinical development. They utilize patient-derived and genetically engineered neural cell types to build unique cell-based assays for modeling neurological and neurodegenerative disorders, aiming to provide more biologically relevant models for studying functional links between targets and phenotypes.Generated from the website

Coherus BioSciences, Inc., based in Redwood City, CA, is dedicated to advancing innovative cancer therapeutics, focusing on next-generation combination therapies to improve treatment outcomes for patients living with hard-to-treat tumors. The company offers a diverse portfolio of immuno-oncology therapies, including the FDA-approved toripalimab-tpzi, aimed at enhancing survival rates for individuals with recurrent or metastatic nasopharyngeal carcinoma. With a strong emphasis on clinical trials and research, Coherus is committed to developing multiple investigational drug candidates that target the tumor microenvironment. Their strategic transformation to Coherus Oncology underlines their exclusive focus on pioneering solutions to combat cancer and support patients in their treatment journeys. Generated from the website